Aerosol Medication Use in COVID-19 Pandemic | Zendy

Musa TOPEL | Zendy; Kurtuluş Aksu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aerosol Medication Use in COVID-19 Pandemic

Author(s) -

Musa TOPEL,

Kurtuluş Aksu

Publication year - 2020

Publication title -

asthma allergy immunology

Language(s) - English

Resource type - Journals

ISSN - 1308-9234

DOI - 10.21911/aai.539

Subject(s) - pandemic , covid-19 , health care , transmission (telecommunications) , medicine , medical emergency , aerosol , infectious disease (medical specialty) , virology , geography , disease , meteorology , economic growth , computer science , outbreak , economics , telecommunications

Administration of aerolized drugs to patients diagnosed with COVID-19 leads to the risk of transmission of patient-generated infectious aerosols to healthcare providers.While the COVID-19 pandemic is ongoing, in order to provide the best treatment for patients and at the same time to protect healthcare providers at the highest level, it is necessary to increase access to information and pay maximum attention to preventive measures.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research